Evidence map›Paper›PMID 42005080›Full record

ArticleAvicenna journal of medicine2026

Antimitochondrial Antibody-Negative Primary Biliary Cholangitis in a Patient with a History of Colon Cancer and Chemotherapy: A Case Report.

Mohammad Berro, Kenana Tawashi, Yahya Ibrahim, Mohammad Sharaf, Somar Ahmad, Ayman Ali

Abstract readCase Reports
In one paragraph

Article in Avicenna journal of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohammad BerroFaculty of Medicine, Damascus University, Damascus, Syria.ORCID 0009-0006-9630-2768
Kenana TawashiDepartment of Oncology, Al Biruni University Hospital, National University Hospital, Damascus, Syria.ORCID 0000-0002-3045-2230
Yahya IbrahimFaculty of Medicine, Damascus University, Damascus, Syria.
Mohammad SharafFaculty of Medicine, Damascus University, Damascus, Syria.
Somar AhmadFaculty of Medicine, Damascus University, Damascus, Syria.
Ayman AliFaculty of Medicine, Damascus University, Damascus, Syria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary biliary cholangitis (PBC) is a chronic, immune-mediated liver disease with progressive destruction of bile ducts, cirrhosis, and liver failure. Diagnosis is usually based on detecting antimitochondrial antibodies (AMA), found in 95% of patients with PBC. However, some patients test negative for AMA and other antibodies, which complicates the diagnosis process. Case Presentation: We report a case of a 57-year-old Syrian woman who presented with fatigue, jaundice, pruritus, and abdominal pain, and her medical history included colon cancer and chemotherapy. Laboratory tests showed liver fibrosis but were negative for AMA, antinuclear antibodies, and anti-smooth muscle antibodies, further complicating the diagnosis. A liver biopsy was performed and showed mixed fibrosis, cholangitis, and cholestasis, which led to the diagnosis of AMA-negative PBC. Conclusions: This case confirms the importance of liver biopsy in unclear cases of primary cholangitis. This case also highlights the patient's history of colon cancer and chemotherapy as a notable clinical observation, generating a hypothesis for a potential association that warrants further systematic investigation. A better understanding of such variants in PBC can enable early diagnosis and improve management strategies for affected patients.

Indexed as

antimitochondrial antibodiesliver diseaseprimary biliary cholangitisursodeoxycholic acid

Identifiers

PMID42005080
PMCPMC13086513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.